中文名稱:PRKCD抗體 | 英文名稱:Rabbit Polyclonal PRKCD Antibody |
品牌: 艾普蒂 | 產(chǎn)地: 武漢 |
保存條件: Stored at -20°C for 3850 year. Avoid repeated freeze / thaw cycles. | 產(chǎn)品類別: 抗體 |
重組: 否 | 應(yīng)用: WB: IHC-P:?IHC-F:?ICC/IF: IP:FC:ChIP:?ELISA |
種屬反應(yīng)性: Human,Mouse,Rat | 宿主: Rabbit |
偶聯(lián)物: 無 | 靶點(diǎn): PRKCD |
WB | 咨詢技術(shù) | Human,Mouse,Rat |
IF | 咨詢技術(shù) | Human,Mouse,Rat |
IHC | 1/25-1/100 | Human,Mouse,Rat |
ICC | 技術(shù)咨詢 | Human,Mouse,Rat |
FCM | 咨詢技術(shù) | Human,Mouse,Rat |
Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
Aliases | MAY1; PKCD; nPKC-delta |
WB Predicted band size | 78 kDa |
Host/Isotype | Rabbit IgG |
Antibody Type | Primary antibody |
Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
Species Reactivity | Human, Mouse, Rat |
Immunogen | Fusion protein of human PRKCD |
Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
Gel: 6%SDS-PAGE, Lysate: 40 μg, Lane: Mouse brain tissue, Primary antibody: P07954(PRKCD Antibody) at dilution 1/350, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 20 seconds
The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P07954(PRKCD Antibody) at dilution 1/30. (Original magnification: ×200)
The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P07954(PRKCD Antibody) at dilution 1/30. (Original magnification: ×200)
以下是3篇關(guān)于PRKCD抗體的代表性文獻(xiàn)及其摘要概括:
1. **文獻(xiàn)名稱**:*Protein Kinase C δ Promotes Apoptosis in Response to Oxidative Stress in Human Hepatocellular Carcinoma Cells*
**作者**:Li W. et al.
**摘要**:該研究利用PRKCD特異性抗體,通過Western blot和免疫熒光技術(shù),證明PRKCD在肝癌細(xì)胞中通過激活線粒體凋亡通路參與氧化應(yīng)激誘導(dǎo)的細(xì)胞死亡,為靶向PRKCD的癌癥治療提供依據(jù)。
2. **文獻(xiàn)名稱**:*PRKCD Regulates Autophagy via mTORC1 Signaling in Neurodegenerative Models*
**作者**:Smith J.R. & Chen X.
**摘要**:作者使用PRKCD抗體進(jìn)行免疫沉淀實(shí)驗(yàn),發(fā)現(xiàn)PRKCD通過抑制mTORC1通路激活自噬,在小鼠阿爾茨海默病模型中減少tau蛋白聚集,提示其在中樞神經(jīng)系統(tǒng)疾病中的保護(hù)作用。
3. **文獻(xiàn)名稱**:*Role of PRKCD in T Cell Receptor Signaling and Autoimmunity*
**作者**:Miyamoto A. et al.
**摘要**:通過流式細(xì)胞術(shù)和ChIP-seq(結(jié)合PRKCD抗體),研究揭示PRKCD通過調(diào)控NF-κB和AP-1轉(zhuǎn)錄活性影響T細(xì)胞活化,其缺失導(dǎo)致小鼠自身免疫性疾病表型,為免疫調(diào)節(jié)機(jī)制提供新視角。
注:上述文獻(xiàn)為示例,實(shí)際引用時(shí)需核對(duì)真實(shí)出版物信息。如需具體文獻(xiàn),建議在PubMed或Web of Science中以“PRKCD antibody”及“PKCδ function”為關(guān)鍵詞檢索近期論文。
The PRKCD antibody is a research tool designed to detect protein kinase C delta (PRKCD), a member of the serine/threonine-specific protein kinase C (PKC) family. PRKCD plays a critical role in cell signaling pathways, regulating processes such as apoptosis, differentiation, proliferation, and immune responses. It is activated by various stimuli, including diacylglycerol (DAG) and calcium, and interacts with signaling molecules like phospholipids and second messengers. Dysregulation of PRKCD has been linked to cancer, autoimmune disorders, and neurodegenerative diseases, making it a target for therapeutic and mechanistic studies.
PRKCD antibodies are used in techniques like Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and flow cytometry to study its expression, localization, and post-translational modifications (e.g., phosphorylation at Thr507). These antibodies are typically raised in hosts such as rabbits or mice, with monoclonal or polyclonal formats available. Specific validation steps, including knockout controls or peptide blocking, are essential to confirm antibody specificity due to potential cross-reactivity with other PKC isoforms.
Researchers utilize PRKCD antibodies to explore its role in cellular stress responses, tumor suppression, and immune regulation, aiding in the development of targeted therapies for diseases associated with PRKCD dysfunction.
成立日期 | 2024-06-24 (2年) | 注冊(cè)資本 | 50萬(元) |
員工人數(shù) | 1-10人 | 年?duì)I業(yè)額 | ¥ 100萬以內(nèi) |
主營行業(yè) | 中間體,化學(xué)試劑 | 經(jīng)營模式 | 貿(mào)易,工廠,試劑,定制,服務(wù) |
產(chǎn)品名稱 | 價(jià)格 | 公司名稱 | 報(bào)價(jià)日期 | |
---|---|---|---|---|
¥1950 |
VIP3年
|
上海滬震實(shí)業(yè)有限公司
|
2025-08-01 | |
詢價(jià) |
VIP3年
|
維百奧(北京)生物科技有限公司
|
2025-08-01 | |
¥1800 |
VIP1年
|
費(fèi)雪(杭州)醫(yī)學(xué)研究有限公司
|
2025-07-28 | |
¥1280 |
湖北艾普蒂生物工程有限公司
|
2025-06-04 |